Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | VHL | P40337 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16317267 | 0.86 | VHL (0.33) | POLBVHLSMN1; SMN2EPHX2 | |
| SCHEMBL19075667 | 0.79 | RIPK1 (0.38) | — | |
| SCHEMBL905280 | 0.75 | HSD17B10 (0.42) | SMN1; SMN2EPHX2 | |
| SCHEMBL16313201 | 0.74 | DPP4 (0.34) | — | |
| SCHEMBL23118976 | 0.73 | MEN1 (0.33) | ESR1MEN1KMT2AAPLNRFFAR3 | |
| SCHEMBL27671157 | 0.73 | ESR1 (0.33) | ESR1MEN1KMT2AAPLNRFFAR3 | |
| SCHEMBL27926042 | 0.71 | KMT2A (0.36) | ESR1MEN1KMT2AAPLNR | |
| SCHEMBL23068014 | 0.71 | ESR1 (0.31) | ESR1MEN1KMT2AAPLNR | |
| SCHEMBL14899050 | 0.69 | ESR1 (0.30) | ESR1MEN1KMT2A | |
| SCHEMBL23897224 | 0.69 | TP53 (0.32) | VHLESR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ATM 4395/4885POLB 2801/4885VHL 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.